10x Genomics (TXG) announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression. The company also announced plans to establish a CLIA-certified laboratory. Together, these efforts mark the beginning of a multi-year research initiative to incorporate single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Balanced Risk/Reward Keeps 10x Genomics at Hold Despite Solid Execution and Discounted Valuation
- 10x Genomics reports preliminary Q4 revenue $166M, consensus $155.95M
- 10x Genomics price target raised to $18 from $15 at TD Cowen
- 10x Genomics price target raised to $20 from $19 at Canaccord
- 10x Genomics price target raised to $18 from $15 at BofA